Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors reduce bodyweight (BW) by creating a negative energy balance. Previous reports have suggested that this BW reduction is mainly loss of body fat and that ~20% of the reduction is lean mass. However, the effects of sodium–glucose cot...

Full description

Bibliographic Details
Main Authors: Hideka Inoue, Katsutaro Morino, Satoshi Ugi, Sachiko Tanaka‐Mizuno, Keiko Fuse, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida, Osamu Sekine, Masahiro Yoshimura, Kiyoshi Murata, Katsuyuki Miura, Hisatomi Arima, Hiroshi Maegawa, the SUMS‐ADDIT‐1 Research group
Format: Article
Language:English
Published: Wiley 2019-07-01
Series:Journal of Diabetes Investigation
Subjects:
Bodyweight
Sodium–glucose cotransporter 2 inhibitor
Treatment drug
Online Access:https://doi.org/10.1111/jdi.12985

Internet

https://doi.org/10.1111/jdi.12985

Similar Items